CLOVER HEALTH INVESTMENTS, CORP. /DE · Hospital & Medical Service Plans

CLOV

Low riskNext report: In 7 days (est.)

View price ↗

The short version

A company still losing money with growing sales. Institutions are adding.

Going well

Sales up 56% in the latest quarter vs a year ago
Sales up 40% last year
No debt reported

Watch out for

About 14 months of cash left at its current burn
Losing money

Money moves

Insiders sold $2.1M in the last 30 days, all through pre-planned sales
Institutions added 14% to their holdings in the quarter ending June 2026 (119 bought, 80 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$4.56-0.9% that day

Company value: $2.5B; Share price times all shares
Price vs sales: 1.0x; No profit over the last year, so this compares value with sales instead
Cash vs value: 3%; Cash as a share of company value

From CLOV's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$743.2M+56% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $2.5B, up 54% from the 12 months before. Over 5 years, sales grew about 23% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of CLOV. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).

Sales growth+30% a yearRecently: +54% a yearProfit margin10%Last 12 months: -3.5%P/E at the end15xMany steady companies trade at 12x to 25xShare count change+3% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$9.2B

Profit in 5 years$920M

Price these guesses point to$21.81+378% vs $4.56 todayAbout +37% a year, before dividends

What today's price needs: with a 10% margin and a 15x P/E, sales could shrink about 4.9% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-26.3%
PassDebt under half of equityNot relying on borrowed money.No debt reported
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-4.4%
MissProfitable every yearSteady profits, not one good year.0 of 7 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$69.0M
MissShare count not growingNot diluting owners. Falling means buybacks.+7.5% in 3 years

Revenue: $1.9B; +40.3% vs prior year
5-year growth: +23.4%/yr; revenue, per year
Total debt: None; 0.00x equity
Current ratio: 1.47x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 5

Revenue: $743.2M; +55.6% YoY
EPS: $0.05; vs -$0.02
Op. margin: 3.8%; +6.0 pts
Free cash flow: $24.5M
Share count: +7.2%; vs a year ago

Insider rating

Last 90 days

44Mixed

Pre-planned sales of $2.1M (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 4.1
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+14.4%

Institutions added 14.4% to their holdings. 119 bought, 80 sold. 2 quarters of net buying in a row.

Shares held by institutions145.8M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+4.4%

Cash runwayAt last year's cash burn

36 months

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

545M

Why low risk

Losing money

Earnings reports

Last 12

Next reportIn 7 days (est.)Estimated from the same quarter last year

Results filedAug 5
Results filedMay 6
Results filedFeb 26
Results filedAug 5, 2025
Results filedMay 6, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

No offerings, red flags or new big holders. Clean record.

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$2.1M5 insiders, 10 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Karen SoaresChief Legal Officer	Sell	19K	$4.66	$90K	2M	Oct 20Filing ↗
-1.2% of their holdings Pre-planned sale (10b5-1) Filed same day
Jamie L. ReynosoCEO, Medicare Advantage	Sell	4K	$4.41	$18K	3M	Oct 19Filing ↗
-0.1% of their holdings Pre-planned sale (10b5-1) Filed 1 day after
Andrew ToyChief Executive Officer	Sell	62K	$4.68	$291K	9M	Oct 15Filing ↗
-0.7% of their holdings Pre-planned sale (10b5-1) Also Director Filed 4 days after
Karen SoaresChief Legal Officer	Sell	15K	$4.68	$69K	2M	Oct 15Filing ↗
-0.9% of their holdings Pre-planned sale (10b5-1) Filed 4 days after
Joseph Clay ThorntonInterim CFO	Sell	5K	$4.68	$21K	1M	Oct 15Filing ↗
-0.4% of their holdings Pre-planned sale (10b5-1) Filed 4 days after
Conrad WaiCEO, Counterpart Health	Sell	24K	$4.68	$111K	1M	Oct 15Filing ↗
-2.2% of their holdings Pre-planned sale (10b5-1) Filed 4 days after
Jamie L. ReynosoCEO, Medicare Advantage	Sell	18K	$4.68	$86K	3M	Oct 15Filing ↗
-0.7% of their holdings Pre-planned sale (10b5-1) Filed 4 days after
Jamie L. ReynosoCEO, Medicare Advantage	Sell	2K	$4.63	$9K	3M	Oct 7Filing ↗
-0.1% of their holdings Pre-planned sale (10b5-1) Filed same day
Jamie L. ReynosoCEO, Medicare Advantage	Sell	9K	$4.42	$39K	3M	Oct 5Filing ↗
-0.3% of their holdings Pre-planned sale (10b5-1) Filed same day
Andrew ToyChief Executive Officer	Sell	319K	$4.19	$1.3M	9M	Oct 1Filing ↗
-3.4% of their holdings Pre-planned sale (10b5-1) Also Director Filed 1 day after